VIR's HDV and HBV treatments remain Vir's primary value drivers, with upcoming catalysts in Q4 2024 and 2025. Find out why ...

Vir Biotechnology (NASDAQ:VIR – Get Free Report) had its price target dropped by stock analysts at Barclays from $28.00 to $26.00 in a report issued on Monday, Benzinga reports. The brokerage ...

Conference call with CEO Dr. Marianne De Backer to be held on November 5 at 10:30 am. Webcast Link Published first on TheFly – the ...

Vir Biotechnology (VIR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick ...

On Friday, Vir Biotechnology Inc (VIR) stock saw a modest uptick, ending the day at $9.26 which represents a slight increase of $1.77 or 23.63% from the prior close of $7.49. The stock opened at $7.14 ...

Vir Biotechnology Inc (VIR) reports increased R&D expenses due to the Sanofi transaction, while advancing its Hepatitis and ...

Q3 2024 Earnings Call Transcript October 31, 2024 Vir Biotechnology, Inc. misses on earnings expectations. Reported EPS is ...

Shares of Vir Biotechnology surged after the company provided updates on its pipeline of potential treatments for hepatitis and cancer. The stock rose 25% to $9.34 in midday trading on Friday. Shares ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ...

GET MORE AI-GENERATED SIGNALS: November 05, 2024, 01:08 am ET, BY Tyler- Contributor| Editor: Thomas H. Kee Jr. ( Follow on LinkedIn) Short VIR slightly under 9.87, target 8.38, stop loss @ 9.9 Check ...

Check the time stamp on this data. Updated AI-Generated Signals for Vir Biotechnology Inc. (VIR) available here: VIR.

SAN ANTONIO - An Indian comedian is bringing his international comedy tour to the Alamo City!On Nov. 16, International Emmy ...